Traws Pharma's top three insider shareholders as of September 09, 2026 are Iain D. Dukes (Chief Executive Officer, 171.13K shares), Nikolay Savchuk (Chief Operating Officer, 150.61K shares), Charles David Pauza (Chief Science Officer Virology, 115.97K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Iain D. Dukes | Chief Executive Officer | 171,130 | 0 | 171,130 | 25.0% | 16 Dec, 2025 |
| 2 | Nikolay Savchuk | Chief Operating Officer | 150,606 | 0 | 150,606 | 22.0% | 16 Dec, 2025 |
| 3 | Charles David Pauza | Chief Science Officer Virology | 115,971 | 0 | 115,971 | 17.0% | 16 Dec, 2025 |
| 4 | Robert Redfield | Chief Medical Officer | 113,919 | 0 | 113,919 | 16.7% | 16 Dec, 2025 |
| 5 | Werner Cautreels | Chief Executive Officer | 109,222 | 0 | 109,222 | 16.0% | 16 Dec, 2025 |
| 6 | Mary Teresa Shoemaker | Director | 6,292 | 0 | 6,292 | 0.9% | 16 Dec, 2025 |
| 7 | Jack E Stover | Director | 6,165 | 0 | 6,165 | 0.9% | 16 Dec, 2025 |
| 8 | Trafford Clarke | Director | 6,157 | 0 | 6,157 | 0.9% | 16 Dec, 2025 |
| 9 | John Harold Leaman | Director | 4,058 | 0 | 4,058 | 0.6% | 16 Dec, 2025 |
| 10 | Steven M Fruchtman | President, Chief Executive Off | 1 | 0 | 1 | 0.0% | 15 Mar, 2024 |
| 11 | Abraham N. Oler | Svp Corp Dev Gen Counsel | 1 | 0 | 1 | 0.0% | 31 Jan, 2022 |
| 12 | Mark Patrick Guerin | Cfo | 1 | 0 | 1 | 0.0% | 20 Jun, 2024 |
| 13 | Mark S. Md Gelder | Chief Medical Officer | 0 | 0 | 0 | 0.0% | 08 Feb, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 09 Jul, 2026 | Charles David Pauza | Chief Science Officer Virology | Acquired A | 97,000 | $0.00 | $0 | 97,000 | Direct |
| 09 Jul, 2026 | Nikolay Savchuk | Chief Operating Officer | Acquired A | 93,000 | $0.00 | $0 | 93,000 | Direct |
| 09 Jul, 2026 | Werner Cautreels | Director | Acquired A | 14,150 | $0.00 | $0 | 14,150 | Direct |
| 09 Jul, 2026 | John Harold Leaman | Director | Acquired A | 14,150 | $0.00 | $0 | 14,150 | Direct |
| 09 Jul, 2026 | Mary Teresa Shoemaker | Director | Acquired A | 14,150 | $0.00 | $0 | 14,150 | Direct |
| 09 Jul, 2026 | Charles Nolan Parker | Chief Financial Officer | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 09 Jul, 2026 | Jack E Stover | Director | Acquired A | 14,150 | $0.00 | $0 | 14,150 | Direct |
| 09 Jul, 2026 | Iain D. Dukes | Chief Executive Officer | Acquired A | 274,000 | $0.00 | $0 | 274,000 | Direct |
| 09 Jul, 2026 | Robert Redfield | Chief Medical Officer | Acquired A | 84,000 | $0.00 | $0 | 84,000 | Direct |
| 09 Jul, 2026 | Trafford Clarke | Director | Acquired A | 14,150 | $0.00 | $0 | 14,150 | Direct |
| 08 Mar, 2026 | Trafford Clarke | Director | Acquired A | 33,435 | $0.00 | $0 | 33,435 | Direct |
| 08 Mar, 2026 | Iain D. Dukes | Chief Executive Officer | Acquired A | 231,336 | $0.00 | $0 | 231,336 | Direct |
| 08 Mar, 2026 | Mary Teresa Shoemaker | Director | Acquired A | 33,435 | $0.00 | $0 | 33,435 | Direct |
| 08 Mar, 2026 | Nikolay Savchuk | Chief Operating Officer | Acquired A | 96,899 | $0.00 | $0 | 96,899 | Direct |
| 08 Mar, 2026 | Robert Redfield | Chief Medical Officer | Acquired A | 108,854 | $0.00 | $0 | 108,854 | Direct |
| 08 Mar, 2026 | Werner Cautreels | Director | Acquired A | 31,258 | $0.00 | $0 | 31,258 | Direct |
| 08 Mar, 2026 | Charles David Pauza | Chief Science Officer Virology | Acquired A | 118,367 | $0.00 | $0 | 118,367 | Direct |
| 08 Mar, 2026 | Jack E Stover | Director | Acquired A | 33,435 | $0.00 | $0 | 33,435 | Direct |
| 08 Mar, 2026 | John Harold Leaman | Director | Acquired A | 33,435 | $0.00 | $0 | 33,435 | Direct |
| 12 Dec, 2025 | Charles David Pauza | Chief Science Officer Virology | Acquired A | 18,471 | $0.00 | $0 | 115,971 | Direct |